bit bio

Bayer subsidiary BlueRock Therapeutics, and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies. Under the terms of the agreement, bit.bio will use its machine learning discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. The agreement also includes options for BlueRock to license bit.bio’s […]

bit.bio has secured a foundational US patent for opti-ox, its precision cell programming and manufacturing technology. opti-ox uses a dual genomic safe harbour approach to cell programming, and the granted US patent covers the use of opti-ox to deterministically activate genetic code in any eukaryotic (cell with a nucleus) cell type. bit.bio uses opti-ox to […]

Mark Kotter, Founder and CEO of bit.bio, talks with Reece Armstrong about different approaches to synthetic biology and its applications in programming stem cells into mature, functional human cells for drug discovery and the creation of next generation. In the last 10 years, synthetic biologists have developed new technologies that have led to some of the […]

Download this new scientific Poster from bit.bio, just revealed at ISSCR 2023. You will discover: How precision reprogramming generates consistent, functional human microglia (ioMicroglia) from iPSCs in just 10 days Independent validation that ioMicroglia undergo phagocytosis of both E. coli particles and amyloid beta particles Independent validation that ioMicroglia show a pro-inflammatory cytokine response to […]

Cell coding company bit.bio has launched a new disease model cell offering enabling scientists to commission disease-relevant mutation of interest.   The company’s new Custom ioDisease Model Cells offering lets scientists choose the disease-relevant mutation they’re interested in. The disease-relevant mutation is engineered into bit.bio’s human ioWild Type cells using CRISPR/Cas9 gene editing.  As disease model cells come […]